FOLH1 and cancer: Since the introduction of anatomical and functional imaging with multiparametric magnetic resonance imaging (MRI) and choline or novel nuclear tracer, such as prostate-specific membrane antigen (PSMA) positron emission tomography–computed tomography (PET–CT), together with early prostate-specific antigen (PSA) detection, the rate of patients with synchronous metastases at diagnosis has increased, reaching at least 5% of all newly diagnosed cancers [2].